Plasma Aβ42 as Biomarker of Prodromal Alzheimer's Disease Progression in Patients with Amnestic Mild Cognitive Impairment: Evidence from the PharmaCog/E-ADNI Study
ContributorsAlbani, Diego; Marizzoni, Moira; Ferrari, Clarissa; Fusco, Federica; Boeri, Lucia; Raimondi, Ilaria; Jovicich, Jorge; Babiloni, Claudio; Soricelli, Andrea; Lizio, Roberta; Galluzzi, Samantha; Cavaliere, Libera; Didic, Mira; Schönknecht, Peter; Molinuevo, José Luis; Nobili, Flavio; Parnetti, Lucilla; Payoux, Pierre; Bocchio, Luisella; Salvatore, Marco; Rossini, Paolo Maria; Tsolaki, Magda; Visser, Pieter Jelle; Richardson, Jill C; Wiltfang, Jens; Bordet, Régis; Blin, Olivier; Forloni, Gianluigi; Frisoni, Giovanni
Published inJournal of Alzheimer's Disease
Publication date2018
Abstract
Keywords
- Amnesic mild cognitive impairment
- Amyloid-beta peptide
- Biomarkers
- Clinical trial
- Clusterin
- PharmaCog 62 project
- Prodromal Alzheimer's disease
Affiliation entities
Research groups
Citation (ISO format)
ALBANI, Diego et al. Plasma Aβ42 as Biomarker of Prodromal Alzheimer’s Disease Progression in Patients with Amnestic Mild Cognitive Impairment: Evidence from the PharmaCog/E-ADNI Study. In: Journal of Alzheimer’s Disease, 2018. doi: 10.3233/JAD-180321
Main files (1)
Article (Published version)
Identifiers
- PID : unige:116118
- DOI : 10.3233/JAD-180321
- PMID : 30149449
Journal ISSN1387-2877